Format

Send to

Choose Destination
Endocrinol Metab Clin North Am. 2019 Jun;48(2):421-427. doi: 10.1016/j.ecl.2019.02.006. Epub 2019 Mar 23.

Osteoporosis and Bone Health in Transgender Persons.

Author information

1
Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle Northeast, WMRB 1028, Atlanta, GA 30322, USA.
2
Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle Northeast, WRMB 1301, Atlanta, GA 30322, USA; Atlanta VA Medical Center, 1670 Clairmont Road Northeast, Decatur, GA 30300, USA. Electronic address: vin.tangpricha@emory.edu.

Abstract

This review summarizes current studies, systematic reviews, and clinical practice guidelines regarding the screening, diagnosis, and treatment of osteoporosis in transgender persons. Gender-affirming hormone therapy has been shown to maintain or promote acquisition of bone density as measured by dual-energy x-ray absorptiometry. No differences in fracture rates have been seen in trans women or men in short, prospective trials. Trans children and adolescents on gonadotropin-releasing hormone may be at risk for decreasing bone density while not on sex steroid hormone replacement. Screening for osteoporosis should be based on clinical factors. Treatment for osteoporosis follows the same guidelines as cisgender populations.

KEYWORDS:

Bone density; Dual-energy x-ray absorptiometry; Gender affirmation; Hormone therapy; Osteoporosis; Transgender

PMID:
31027549
PMCID:
PMC6487870
[Available on 2020-06-01]
DOI:
10.1016/j.ecl.2019.02.006

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center